Kyomarc (bevacizumab)
- Region
- 🇪🇺 EU
- Active substance
- bevacizumab
- Company
- Amgen Europe B.V.
- Status
- Application withdrawn
- Therapeutic area
- Carcinoma, Renal Cell; Carcinoma, Bronchogenic; Fallopian Tube Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms
- Application
- EMEA/H/C/004360
- ATC
- L01XC07
- Official record
- www.ema.europa.eu
Indication
Treatment of breast cancer, non-small cell lung cancer, renal cell cancer, advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, platinum-sensitive epithelial ovarian, fallopian tube or primary
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Mvasi Authorised · Amgen Europe B.V.
- 🇪🇺 Aybintio Authorised · Samsung Bioepis NL B.V.
- 🇪🇺 Lytenava Authorised · Outlook Therapeutics NL B. V.
- 🇪🇺 Orblid Application withdrawn · Laboratoires Delbert
- 🇪🇺 Abevmy Authorised · Biosimilar Collaborations Ireland Limited
- 🇪🇺 Zirabev Authorised · Pfizer Europe MA EEIG
- 🇪🇺 Avzivi Authorised · FGK Representative Service GmbH
- 🇪🇺 Alymsys Authorised · Mabxience Research SL
- 🇪🇺 Oyavas Authorised · STADA Arzneimittel AG
- 🇪🇺 Vegzelma Authorised · Celltrion Healthcare Hungary Kft.
- 🇪🇺 Avastin Authorised · Roche Registration GmbH
- 🇪🇺 Onbevzi Withdrawn · Samsung Bioepis NL B.V.
Follow Kyomarc
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.